PARADIGM-2:OlaPArib and RADIotherapy or olaparib and radiotherapy plus temozolomide in newly-diagnosed Glioblastoma stratified by MGMT status: 2 parallel phase I studies
Latest Information Update: 14 Oct 2022
At a glance
- Drugs Olaparib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms PARADIGM-2
- 07 Jan 2021 The January 2021 status update of the ISRCTN record is showing the last edited date as 05 Aug 2020, which seems incorrect. Therefore, I have indexed the bundle received date as the event date for status change.
- 01 Jan 2021 Status changed from recruiting to completed.
- 05 Aug 2020 Status changed from active, no longer recruiting to recruiting.